GRIMES & Co WEALTH MANAGEMENT LLC Trims Stock Holdings in Stryker Corporation $SYK

GRIMES & Co WEALTH MANAGEMENT LLC trimmed its holdings in Stryker Corporation (NYSE:SYK) by 27.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 6,367 shares of the medical technology company’s stock after selling 2,400 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Stryker were worth $2,238,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the third quarter worth approximately $27,000. CGC Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter worth approximately $29,000. Strive Asset Management LLC purchased a new stake in shares of Stryker in the third quarter worth approximately $30,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker in the third quarter worth approximately $34,000. Finally, Copia Wealth Management increased its holdings in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 69 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 3.0%

Shares of NYSE SYK opened at $285.49 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $109.34 billion, a PE ratio of 33.04, a price-to-earnings-growth ratio of 1.85 and a beta of 0.80. The stock’s fifty day simple moving average is $340.37 and its two-hundred day simple moving average is $355.17. Stryker Corporation has a 12-month low of $284.95 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Analyst Upgrades and Downgrades

Several research analysts have commented on SYK shares. William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup reduced their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.